---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-000092"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-01-02T23:59:59+00:00"
generated_at: "2026-05-28T18:08:32.804200+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Karyopharm appoints Lori Macomber as CFO effective Jan 3, 2025

## Summary
- Macomber previously CFO at Legend Biotech, will serve as EVP, CFO and Treasurer.
- Annual base salary of $475,000; target annual bonus of 45% of base salary.
- Inducement equity: option for 650,000 shares and 160,000 RSUs, vesting over 4 and 3 years.
- Kristin Abate, interim principal financial officer, will step down on Jan 3, 2025.
- Severance includes one month base salary per month of service (max 12 months), enhanced upon change in control.

## SEC filing metadata
- accession: 0000950170-25-000092
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-01-02T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000095017025000092/0000950170-25-000092-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000095017025000092/kpti-20250102.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-000092
- JSON: https://secwatch.observer/filing/0000950170-25-000092.json
- Plain text: https://secwatch.observer/filing/0000950170-25-000092.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.